NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, B. Andreadis, Nancy L. Bartlett, Lihua E. Budde, Paolo F. Caimi, Julie Chang, Beth Christian, Sven deVos, Bhagirathbhai Dholaria, Luis Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco J. Hernandez‐Ilizaliturri, Boyu Hu, Yasmin Karimi, Chris R. Kelsey, Rebecca L. King, Justin Kline, Susan Krivacic, Ann S. LaCasce, Daniel J. Landsburg, Megan S. Lim, Marcus Messmer, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Naoyuki G. Saito, Stephen D. Smith, Lode J. Swinnen, Joseph M. Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar
Abstract
The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.